This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit    January 08, 2015


 




41st Annual Anatomic Pathology Conference

Feb. 13-15, 2015 at Disney's Contemporary Resort in Orlando, Florida

You are invited to join the Florida Society of Pathologists at the 41st Annual Anatomic Pathology Conference at Disney's Contemporary Resort® in beautiful Lake Buena Vista, Florida!

READ MORE




UnitedHealthcare pushes back start date for making claims-payment decisions
Dark Daily
Physicians, pathologists, and clinical laboratories in Florida got a late Christmas present. UnitedHealthcare postponed the date when its medical laboratory benefit-management pilot program in Florida, administered by BeaconLBS, would affect claims payments. This was welcome news, because, beginning Jan. 1, if physicians serving UHC patients had failed to use the BeaconLBS system to obtain pre-notification or pre-authorization for 82 medical laboratory tests, the physicians or labs performing the tests would not be paid by UHC—nor could clinical labs and pathology groups in the UHC provider network bill patients for these tests.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Watching and waiting for codes and fees
Genetic Engineering & Biotechnology News
Clinical laboratories will be watching and waiting in the new year for the Centers for Medicare and Medicaid Services (CMS) to resolve several unsettled issues concerning fees for molecular pathology tests, as well as coding for drug-screening tests. CMS approved 21 new codes for advanced genomic studies such as exome sequencing and whole genome sequencing, as well as a range of hereditary and cancer/somatic mutation genetic panels.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


FDA outlines ways to assess analytical, clinical performance of NGS ahead of February workshop
GenomeWeb
The US Food and Drug Administration is considering a standards-based approach for assessing the analytical performance of next-generation sequencing diagnostic tests and using centralized curated databases to evaluate their clinical performance, according to a recent paper published by the agency. The preliminary discussion paper, posted on the FDA's website, outlines possible ways the agency might regulate NGS tests in the future and provides discussion points for a one-day public workshop entitled "Optimizing FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests" that the FDA will hold at the National Institutes of Health campus in Bethesda, Md., on February 20.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


End of cancer genome project prompts rethink of research strategy
Scientific American
A mammoth U.S. effort to genetically profile 10,000 tumors has officially come to an end. Started in 2006 as a U.S. $100-million pilot, The Cancer Genome Atlas is now the biggest component of the International Cancer Genome Consortium, a collaboration of scientists from 16 nations that has discovered nearly 10 million cancer-related mutations. The question is what to do next.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


1-year program trains medical laboratory scientists
Times Record News
A precise choreography of specialties often determines the outcome of patient care at United Regional Health Care System, most of them seen throughout the process including doctors, nurses, a variety of therapists, radiology and the list goes on. The type of treatment or course of action for some disease processes is often based on the findings of a highly trained group of professionals who look for the proverbial needle in the haystack — medical laboratory scientists, more commonly called medical technologists. What makes the career field at United Regional unique is most of them were trained in the Texas hospital's one-year program.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Study: Breast cancer risk for women with atypical hyperplasia greater than previously thought
News Medical
Women with atypical hyperplasia of the breast have a higher risk of developing breast cancer than previously thought, a Mayo Clinic study has found. Results of the study appear in a special report on breast cancer in the New England Journal of Medicine.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Healthcare spending may reach $10,000 per person this year
Fierce Health Finance
The year 2015 may be the time where healthcare spending in the United States reaches a specific milestone: $10,000 per person. The National Healthcare Expenditure may reach $3.2 trillion this year, according to Forbes magazine. Based on a population of 320 million Americans, that would mean spending $10,000 per person. That number may be reached despite the fact that the Centers for Medicare & Medicaid Services reported healthcare spending in 2013 was the lowest on record, with an increase of 3.6 percent.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Miss an issue of Pathology Today? Click here to visit the Pathology Today archive page.


Doctors face huge Medicare and Medicaid pay cut in 2015
Forbes
If you thought it was getting increasingly difficult for Medicare and Medicaid patients to see a doctor, you're right — and that problem may get even worse in 2015. Doctors who still accept Medicare patients could see an average reduction of 21.2 percent in Medicare reimbursement rates, according the Department of Health and Human Services. And a new Urban Institute study claims primary care physicians who still take Medicaid patients could see an average reduction of 42.8 percent.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Blood test for prostate cancer investigated
Vanderbilt University Medical Center via ScienceDaily
A method for detecting 'cell-free' tumor DNA in the bloodstream has been developed by scientists who believe that the technique will be transformative in providing improved cancer diagnostics that can both predict treatment outcomes and monitor patient responses to therapy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE

Disclaimer: The authors, editors, and the Florida Society of Pathologists (FSP) Executive Committee affiliated with "Florida Pathology Today" e-Newsletter cannot and do not warrant the completeness, accuracy, non-infringement, merchantability, timeliness or fitness for a particular purpose of the information or views contained within this publication, or available through the links provided within articles contained within this publication.

FSP has no control over and does not officially endorse the content of the information available on the links contained in the "Florida Pathology Today" or links imbedded in articles within the "Florida Pathology Today." These links are provided as a courtesy only. Linked sites are not a part of the "Florida Pathology Today." The owners of those linked sites, and not FSP, own the intellectual property rights to the material on the linked sites. FSP cannot certify the accuracy of material published on linked sites. Additionally, the contents of this e-Newsletter and the above referenced links, including any advice, suggestions, and/or recommendations have NOT been generated as part of any professional evaluation.

The authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" e-Newsletter shall not be liable to anyone for any loss or injury caused in whole or in part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting or delivering this e-Newsletter and any information included in this e-Newsletter.

Under no circumstances will the authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" be liable to you or anyone else for any decision made or any action taken by you or anyone else in reliance on such information or view, or for any incidental, consequential, special, or similar damages even if advised of the possibility of such damages.

The above warranties are the only warranties of any kind either expressed or implied, including warranties of merchantability or fitness for any particular purpose.

 



Pathology Today
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Esther Cho, Content Editor, 469.420.2671  
Contribute news


Learn how to add us to your safe sender list so our emails get to your inbox.

This edition of Pathology Today was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Dec. 23, 2014
Dec. 10, 2014
Nov. 26, 2014
Nov. 12, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063